SAGE Therapeutics Inc (NASDAQ:SAGE) Receives $202.15 Consensus PT from Brokerages

Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) have been given an average recommendation of “Buy” by the seventeen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $202.15.

Several equities research analysts have recently weighed in on the company. BidaskClub raised SAGE Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 10th. LADENBURG THALM/SH SH set a $220.00 price objective on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Wedbush assumed coverage on SAGE Therapeutics in a research note on Wednesday, May 22nd. They set an “outperform” rating and a $207.00 price objective for the company. Raymond James reissued a “market perform” rating on shares of SAGE Therapeutics in a research note on Friday, April 26th. Finally, Oppenheimer set a $170.00 price objective on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Sunday, May 5th.

In other news, Director Steven M. Paul sold 3,775 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $161.05, for a total value of $607,963.75. Following the completion of the sale, the director now owns 272,777 shares of the company’s stock, valued at $43,930,735.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jeffrey M. Jonas sold 94,264 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $174.75, for a total value of $16,472,634.00. Following the completion of the sale, the chief executive officer now directly owns 116,023 shares of the company’s stock, valued at approximately $20,275,019.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 291,121 shares of company stock valued at $49,791,439. Corporate insiders own 4.60% of the company’s stock.

Several institutional investors have recently modified their holdings of SAGE. Jennison Associates LLC boosted its position in shares of SAGE Therapeutics by 163.0% in the first quarter. Jennison Associates LLC now owns 2,355,614 shares of the biopharmaceutical company’s stock worth $374,660,000 after buying an additional 1,459,950 shares during the period. Janus Henderson Group PLC boosted its position in shares of SAGE Therapeutics by 440.6% in the first quarter. Janus Henderson Group PLC now owns 1,668,629 shares of the biopharmaceutical company’s stock worth $265,395,000 after buying an additional 1,359,947 shares during the period. FMR LLC boosted its position in shares of SAGE Therapeutics by 8.2% in the first quarter. FMR LLC now owns 7,608,239 shares of the biopharmaceutical company’s stock worth $1,210,091,000 after buying an additional 575,163 shares during the period. Partner Fund Management L.P. acquired a new stake in shares of SAGE Therapeutics in the fourth quarter worth $48,448,000. Finally, TimesSquare Capital Management LLC acquired a new stake in shares of SAGE Therapeutics in the first quarter worth $78,762,000.

Shares of SAGE stock traded down $3.20 during mid-day trading on Monday, hitting $172.64. 214,761 shares of the stock traded hands, compared to its average volume of 570,111. SAGE Therapeutics has a twelve month low of $79.88 and a twelve month high of $178.16. The stock has a market cap of $8.83 billion, a PE ratio of -21.37 and a beta of 2.66. The company has a debt-to-equity ratio of 0.03, a quick ratio of 20.06 and a current ratio of 20.06.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.17) by ($0.20). The firm had revenue of $0.47 million during the quarter. During the same quarter in the previous year, the firm posted ($1.68) EPS. Equities research analysts predict that SAGE Therapeutics will post -13.19 earnings per share for the current year.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: What is Net Asset Value (NAV)?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.